KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.
Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
The strategy is to develop a portfolio of oral molecules and evaluate multiple candidates in the clinic to provide a best-in-class therapy for HAE patients. As part of this strategy, we will select molecules whose properties can support multiple therapies for HAE patients, such as for prophylactic as well as acute treatment.
We are advancing multiple drug candidates into Phase 1 clinical trials and additional program candidates are in preclinical development. Our most advanced compound, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has successfully completed its first‑in‑human study in patients with DME and began a Phase 2 clinical trial in 2017. In October 2017, we entered into a collaboration agreement with Merck for KVD001 as well as future oral DME compounds based upon plasma kallikrein inhibition.
We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.
Our offices are in Cambridge, MA, USA and Salisbury, UK.